Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
Man‐Fung Yuen(University of Hong Kong - Shenzhen Hospital), T. Jesse Kwoh(Université Paris-Sud), Melanie Paff, Shihyun You(GlaxoSmithKline (United States)), Jung‐Hwan Yoon(Seoul National University), Jeong Heo(National Cancer Center), Jennifer Cremer(Southern Medical University), Dickens Theodore, C. Frank Bennett(Pennsylvania State University), Yvonne Tami(Electronic BioSciences (United States)), Tao Yu(Nanfang Hospital), Sung Jae Park(Inje University Busan Paik Hospital), Fiona Campbell(University of Birmingham), Phillip Yates(GlaxoSmithKline (United Kingdom)), Jeong-Won Jang(The Catholic University of Korea Seoul St. Mary's Hospital), Robert C. Elston(University of North Carolina at Chapel Hill)
Cited by 156
Related Papers
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
|Clinical Infectious Diseases|2020|5k
What is meant by intention to treat analysis? Survey of published randomised controlled trials
|BMJ|1999|2.2k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Effectiveness of brief alcohol interventions in primary care populations
|Cochrane Database of Systematic Reviews|2018|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k